Back Members
Main research interest: understanding the biology underlying cancer complexity as well as the tumor-microenvironment crosstalk, with the ultimate goal to found biomarkers useful for cancer control. Currently, she is trying to stratify CRC patients on the basis of the molecular characteristics and the level of lymphocytic infiltration of their tumors. Also, NGS technique has been used to identify immunogenic mutations susceptible to activate the patients’ immune system that can be used as a cancer vaccine. A pre-clinical study in mice is on-going.
CANCER, MOLECULAR AND CELLULAR BIOLOGY, BIOINFORMATICS, SYSTEMS BIOLOGY, INTERACTION NETWORKS, OMICS DATA INTEGRATION, BIOMARKERS

EDUCATION

2013 – Online Postgraduate in Biostatistics at the Open University of Catalonia (UOC).

2009 – PhD in Biology, University of Barcelona (UB), Barcelona.

2005 – Master’s degree in Bioinformatics, International University of Andalusia (UNIA).

2005 – Master’s degree in Biotechnology, University of Barcelona (UB), Barcelona

2003 – Degree in Biology, University of Barcelona (UB), Barcelona.

 

WORK EXPERIENCE
2010 – current: Postdoctorate researcher at Unit of Biomarkers and Susceptibility, Catalan Institute of Oncology (ICO), Barcelona.
2005 – 2009: Predoctoral student in the Molecular Oncology laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona.

 

OTHER
31 peer-reviewed papers.

35 posters in national and international meetings.

2012-current: Reviewer in the journal “Clinical and Translational Oncology”

2011-current: Member of the Spanish Association for Cancer Research (ASEICA)

2011-current: Member of the European Association for Cancer Research (EACR)

2010 – awarded Spanish Association Against Cancer (AECC) post-doctoral grant

2007 -awarded travel grant to present a communication (poster) in the MetaBre/ Brecosm breast cancer and metastasis conference (Rome, Italy).

 

PATENTS
  • Pamplona R, Sierra A, Oliva B, Moreno V, Gil JM

Method for determining the risk of developing brain metastasis and a kit to carry out said method

PCT/EP2010/057947

Priority Data: P 200930294 10.06.2009 ES

 

  • Moreno V, Crous-Bou M, Sole X, Cordero D, Berenguer A, Guino E, Sanz-Pamplona R

Serum biomarker for diagnosing colorectal cancer

Registro: EP2680003 A1, Priority date 28/06/12, published 01/01/2014

Titular: IDIBELL, ICO, UB

 

SELECTED PUBLICATIONS

  • Mutanome and expression of immune response genes in microsatellite stable colon cancer.

Sanz-Pamplona R, Gil-Hoyos R, López-Doriga A, Alonso MH, Aussó S, Molleví DG, Santos C, Sanjuán X, Salazar R, Alemany R, Moreno V. Oncotarget. 2016 Apr 5;7(14):17711-25.

 

  • Algorithmic methods to infer the evolutionary trajectories in cancer progression.

Caravagna G, Graudenzi A, Ramazzotti D, Sanz-Pamplona R, De Sano L, Mauri G,Moreno V, Antoniotti M, Mishra B.  Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):E4025-34.

 

  • Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer.

Sanz-Pamplona R, Lopez-Doriga A, Paré-Brunet L, Lázaro K, Bellido F, Alonso MH, Aussó S, Guinó E, Beltrán S, Castro-Giner F, Gut M, Sanjuan X, Closa A, Cordero D, Morón-Duran FD, Soriano A, Salazar R, Valle L, Moreno V. Clin  Cancer Res. 2015 Oct 15;21(20):4709-18

 

  • Intrinsic cancer subtypes–next steps into personalized medicine.

Santos C, Sanz-Pamplona R, Nadal E, Grasselli J, Pernas S, Dienstmann R, Moreno V, Tabernero J, Salazar R.  Cell Oncol (Dordr). 2015 Feb;38(1):3-16. Review.

 

  • Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer.

Sanz-Pamplona R, Berenguer A, Cordero D, Molleví DG, Crous-Bou M, Sole X, Paré-Brunet L, Guino E, Salazar R, Santos C, de Oca J, Sanjuan X, Rodriguez-Moranta F, Moreno V. Mol Cancer. 2014 Mar 5;13:46.